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Implication for health policy/practice/research/medical education:
Lactulose as a prebiotic can improve Bifidobacteria and Lactobacilli counts. The aim is the evaluation of lactulose on intestinal 
flora of chronic kidney disease patients. We used lactulose and compared the bifidobacteria and lactobacillus colony counts and 
also nitrogenous waste products with control patients. There was significant reduction of urea, creatinine in improvement of 
Bifidobacteria and Lactobacillus counts.  
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Introduction: Lactulose is a prebiotic with bifidogenic and urea reduction effects. It can 
improve Bifidobacteria and Lactobacilli counts in healthy humans and it may possibly have 
similar effects in chronic kidney disease (CKD) patients. 
Objectives: To investigate the effect of lactulose on fecal microflora of patients with CKD.
Patients and Methods: Thirty-two patients with stages 3 and 4 of CKD (43.8% male with 
mean age of 58.09 ± 12.75 years) were randomly assigned to intervention (n = 16) and control 
(n = 16) groups. Patients in intervention group received 30 mm lactulose syrup three times 
a day for an 8-week period. Control group received placebo 30 mm three times a day. A 
fecal sample was obtained from all patients at the beginning and at the end of the study and 
Bifidobacteria and Lactobacilli was counted. 
Results: Creatinine (Cr) significantly decreased in intervention group (3.90 ± 1.43 to 
3.60 ± 1.44, P = 0.003) and increased in control group (3.87 ± 2.08 to 4.11±1.99, P = 0.03). 
Although Bifidobacterial and Lactobacilli counts were similar before intervention, they 
were significantly higher at the end of the study in lactulose group (P = 0.01 and P = 0.04, 
respectively). Lactulose led to significant increase in fecal Bifidobacterial counts (3.61 ± 0.54 
to 4.90 ± 0.96, P < 0.001) and Lactobacilli counts (2.79 ± 1.00 to 3.87 ± 1.13, P < 0.001), while the 
change in placebo group was not significant.
Conclusion: Lactulose administration will increase Bifidobacteria and Lactobacillus counts 
in patients with CKD. 
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Introduction
In the last decades, considerable efforts have been di-
rected at improving human (as well as animal) health or 
preventing disease by the use of functional foods to which 
prebiotics and probiotics belong (1,2). Prebiotics are non-
digestible and selectively fermented food ingredients that 
modulates beneficial gastrointestinal microflora, both in 
the composition and/or their activities, thus generating 
benefits to human health. Lactobacilli and Bifidobacteria 
are the usual target genera for prebiotics (3,4). Numerous 
scientists investigated the health-promoting effect of pre-
biotics like indigestible sugars, e.g. fructooligosaccharides, 
inulin and lactulose (5,6). 
The positive effects of lactulose on colonic metabolism 
in human is well known (7). Lactulose is a commercially 
available disaccharide that is used as a drug in the treat-
ment of hepatic encephalopathy and chronic constipation 
(8,9), which has been shown to stimulate the growth of 
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Bifidobacteria (10). 
Uremia is an illness that accompanies renal failure and 
chronic kidney disease (CKD). Uremic illness is consid-
ered to be due largely to the accumulation of organic waste 
products that are normally cleared by the renal. However, 
uremic products are also generated in the gastrointesti-
nal tract (GIT). Toxins generated in, or introduced into 
the body via the intestine, like advanced glycation end 
products, phenols, and indoles, all may contribute to the 
pathogenesis of CKD. Another problem in CKD patients 
is the prolonged colonic transit time that promotes ure-
mia retention and absorption. It is supposed that prebiot-
ics like lactulose have a therapeutic role in maintaining a 
metabolically balanced GIT with increased beneficial GIT 
microflora, and would reduce progression of CKD and as-
sociated uremia (11-13). In CKD, lactulose could promote 
fecal excretion of water, sodium, potassium, ammonium, 
urea, creatinine (Cr) and protons (14). In our previous 
study, we showed that lactulose administration in CKD 
patients could decrease levels of various deleterious ele-
ments, especially nitrogen products (15).
Due to the role of lactulose as a prebiotics in GIT and its 
possible positive effects on CKD patients, we aim to evalu-
ate the effects of lactulose supplementation on fecal mi-
croflora in these patients.
Patients and Methods
Study population
In this randomized controlled clinical trial, 32 patients 
with CKD in the stages 3 and 4 were recruited and ran-
domly assigned to intervention (n = 16) and control 
(n = 16) groups. During the study no patients were exclud-
ed or withdrawn in any groups (Figure 1). Patients over 
18 years old with an estimated glomerular filtration rate 
(eGFR) ≤60 ml/min/1.73 m2 and stages 3 and 4 of CKD, 
with no history of gastrointestinal or metabolic disease or 
previous surgery (apart from appendectomy), and with-
out antibiotic treatment or any other medical treatment 
influencing intestinal microbiota especially probiotics, 
prebiotics and symbiotics during the 3 months before the 
start of the study were included. Subjects were advised 
to maintain their usual diet during the study period and 
to avoid the intake of fermented milk products and food 
components containing high quantities of fermentable 
carbohydrates. The treatment would be stopped if any ma-
jor complications would have happened and if any patient 
had diarrhea due to lactulose use, the treatment would be 
stopped and after a period start with lower dosage. Those 
could not keep up with the study protocol or with drug 
intolerance were excluded. The subjects did not have to 
restrict their everyday diet, medication or daily activities. 
Those drugs which induce constipation such as AST-120, 
polystyrene sulfonate and potassium binders were not 
administered. 
Study protocol
The study was conducted over an 8-week period. Patients 
in case group received 30 mm lactulose syrup (Zahravi 
Co, Tabriz, Iran) three times a day. The doses adminis-
tered were chosen based on therapeutic recommendations 
for CKD patients in a way that subjects did not suffer from 
negative effects or discomfort. Control group received CONSORT 2010 Flow Diagram 
Assessed for eligibility (n= 68) 
Excluded (n=  36 ) 
   Not meeting inclusion criteria (n=  22) 
   Declined to participate (n= 14 ) 
Analysed (n= 16)  
 Excluded from analysis (n= 0) 
Lost to follow-up (n=0) 
Discontinued intervention (n=0) 
Allocated to intervention (n= 16) 
 Received allocated intervention (n= 16) 
 Did not receive allocated intervention  (n= 0) 
Lost to follow-up (n=0 ) 
Discontinued intervention (n=0) 
Allocated to intervention (n= 16) 
 Received allocated intervention (n=  16) 
 Did not receive allocated intervention  (n=  0) 
Analysed (n= 16) 
 Excluded from analysis (n= 0) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n= 32) 
Enrollment 
Figure 1. Patients who allocated to receive lactulose and control group.
Journal of Renal Injury Prevention, Volume 5, Issue 3, September 2016 http://journalrip.com  164 
Tayebi-Khosroshahi H et al
placebo 30 mm three times a day. All patients were visited 
weekly in order to evaluate the possible side effects and as-
sessing their adherence to medication. The same company 
prepared a placebo solution with the same color and taste.
Fecal analysis
A fecal sample was obtained from all patients at the begin-
ning and the end of the study. They were collected in plas-
tic containers under anaerobic conditions, immediately 
stored at 4°C and analyzed within 3 hours. Stool samples 
were homogenized with a high-speed blender and serially 
diluted 10-fold in solution for anaerobes (saline, glucose 
and cysteine). A volume of 100 mL of each dilution was 
inoculated in appropriate agars. Bifidobacteria and Lacto-
bacilli were cultured for respectively 5 and 3 days at 37°C 
in anaerobic conditions (Gas Pak A system, BBL, Cock-
eysville, MD, USA) with Anaerocult A. Bifidobacteria 
were counted on the Beerens medium (Beerens, 1991); 
Lactobacilli were counted on the Rogosa medium. 
Ethical issues 
The research followed the tenets of the Declaration of Hel-
sinki. Informed consents were obtained from parents and 
the research was approved by the Ethics Committee of Ta-
briz University of Medical Sciences. This clinical trial had 
a registration ID: IRCT201105302858N2 in Iran (http://
www.irct.ir/).
Statistical analysis
Statistical analyses were performed using the SPSS version 
16.0 (SPSS Inc., Chicago, Illinois). Faecal concentrations 
of bacteria were expressed as log colony forming unit 
(CFU)/g wet weight. Continuous values were expressed as 
mean ± stan dard deviation (SD) and categorical variables 
were expressed as percentages. The categorical parameters 
were compared by χ2 tests or Fisher’s exact test. The con-
tinuous variables before and after intervention between 
groups was compared with independent t test and within 
each group was compared with paired samples t test. A P 
value less than 0.05 was considered significant.
Results
Thirty-two CKD patients (18 female with mean age 
of 58.09 ± 12.75 years) were divided into intervention 
(n = 16) and control (n = 16) groups. Patients’ baseline 
findings are demonstrated in Table 1. There was no differ-
ence in baseline findings between groups. 
Table 2 demonstrates the laboratory findings before and 
after intervention in both groups. There were no signifi-
cant differences between groups in hemoglobin (Hb), Cr 
and blood urea nitrogen (BUN) before and at the end of 
the study. Comparing the results before and at the end of 
the study within each group, we observed that Cr signifi-
cantly decreased in intervention group (from 3.90 ± 1.43 
to 3.60 ± 1.44, P = 0.003). In control group receiving pla-
cebo, Hb was significantly decreased (from 11.080.82 to 
10.93 ± 0.92, P = 0.02) and Cr was significantly increased 
(from 3.87 ± 2.08 to 4.11 ± 1.99, P = 0.03). The percentage 
Table 1. Patients’ baseline findings
Intervention Control P value
Age (y) 59.31 ± 12.97 56.88 ± 12.84 NS
Gender, male, n (%) 9 (56.3%) 5 (31.3%) NS
Etiology of CKD
Diabetes mellitus 4 8
Hypertension 6 4
Glomerulonephritis 1 2
Polycystic kidney disease 2 0
Unknown 3 2
Abbreviations: CKD, Chronic kidney disease; NS: not significant.
Table 2. Laboratory findings before and after intervention in both 
groups
Intervention Control P value
Hb (g/dL)
Before 11.00 ± 1.36 11.08 ± 0.82 NS
At the end 11.16 ± 1.19 10.93 ± 0.92 NS
Cr (mg/dL)
Before 3.90 ± 1.43 3.87 ± 2.08 NS
At the end 3.60 ± 1.44 4.11 ± 1.99 NS
BUN (mg/dL)
Before 55.31 ± 14.54 53.88 ± 14.68 NS
At the end 48.38 ± 15.54 55.38 ± 11.98 NS
of change in Cr level during the trial was calculated and 
showed that in intervention group Cr was decreased while 
it was increased in control group and the difference was 
significant (-8.01 ± 2.40 versus 10.20 ± 4.94; P = 0.002).
Table 3 demonstrates the effect of 8-week ingestion of lact-
ulose or placebo (30 mL/d) on the fecal bacterial counts in 
CKD patients. Before intervention, there were no signifi-
cant differences between groups in fecal Bifidobacterial 
counts and Lactobacilli counts. At the end of the study, 
fecal Bifidobacterial counts and Lactobacilli counts were 
significantly higher after lactulose consumption com-
pared to placebo ingestion. Lactulose led to significant 
increase in fecal Bifidobacterial counts (P < 0.001) and 
Lactobacilli counts (P < 0.001). Placebo consumption in 
control group did not lead to any significant fecal Bifido-
bacterial (P = 0.13) or Lactobacilli (P = 0.15) count change. 
There were not any considerable side effects regarding 
lactulose use.
Discussion
In this randomized clinical trial we evaluated the effects 
of lactulose on fecal microflora in CKD patients and ob-
served significant increase in fecal bifidobacterial and 
lactobacillus count in patients receiving lactulose, which 
showed no difference in placebo group. 
There are no studies evaluating lactulose effects on GIT 
microflora in CKD patients. Previous studies on healthy 
humans have shown significant increase in fecal bifido-
bacteria counts in healthy and even in cirrhotic patients 
and those with idiopathic constipation (10,16,17). How-
ever, unlike our findings, none of these studies could show 
any significant changes in lactobacillus counts. It is shown 
in other prebiotics except lactulose that Lactobacilli count 
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significantly increases after prebiotic administration 
(18,19). In contrast to aforementioned results, Bouhnik et 
al (20) observed that lactulose was not bifidogenic and did 
not cause significant increase in the bifidobacteria count; 
however the study was performed on healthy subjects and 
in duration of 8 days which would affect the results. 
Accumulation of urea in the body fluids in humans and 
animals with renal failure leads to its heavy influx into the 
GIT (21), which is compounded by microbial coloniza-
tion of the upper intestinal tract and dramatic change in 
the composition of the gut microbiome (22). This micro-
bial colonization in intestine in CKD patients are mostly 
due to inefficient protein assimilation in the small intes-
tine resulting in more protein entering the large intestine, 
prolonged colonic transit time, and increased luminal pH 
secondary to increased colonic urea diffusion (11). As 
well it is demonstrated that colonic microbial activity may 
contribute to uremic solute production (23). New studies 
are aim to find a way to reduce unwanted bacterial colo-
nization by increasing beneficiary microflora including 
bifidobacteria and lactobacillus. This improvement could 
produce compounds to inhibit potential pathogens, pro-
duce digestive enzymes and reduce blood ammonia levels 
and constipation (24). 
The prebiotic lactulose has the potential to alter fecal 
flora (25). It is neither absorbed nor metabolized in the 
upper GIT but is degraded to organic acids by bacteria 
of the proximal colon (26). Lactulose mostly can act as a 
substrate for many lactic acid bacteria and increase their 
amount mostly Bifidobacteria and Lactobacilli. It also de-
creases significantly the number of (lecithinase-positive) 
clostridia and Bacteroidaceae decreased (27). However, 
we only evaluated the changes in the amount of Bifido-
bacteria and Lactobacilli.
The low concentrations of Lactobacilli and Bifidobacte-
ria have been shown previously in renal failure patients 
(28,29). It is suggested that prebiotic intake may be partic-
ularly effective for subjects exhibiting low intrinsic num-
bers of Bifidobacterial (30,31). It is possible that prebiot-
ics like lactulose be also effective in subjects with lower 
Lactobacilli count. CKD patients in our study had very 
lower Bifidobacteria and Lactobacilli counts than healthy 
subjects reported in the literature which was significantly 
increased after lactulose administration. 
Elevated levels of p-cresol have recently been demonstrat-
ed to be correlated to a higher mortality in uremic syn-
drome (32). The exact pathogenic mechanisms occurring 
in case of kidney disease are not completely understood 
today. Therefore, strategies that counteract the accumula-
tion of p-cresol and other protein fermentation metabo-
lites might constitute a significant improvement in the 
management of those patients. De Preter and colleagues 
observed a significant reduction of the urinary 15N and 
p-cresol (as a part of uremic toxins) excretion after the in-
take of lactulose, which was accompanied by a significant 
increase in the fecal 15N output (33,34). These studies in-
dicate that subjects with higher baseline levels of uremic 
toxins would show a higher response to prebiotic dosing. 
The mechanism of increasing bifidobacteria and lactoba-
cillus after lactulose administration is ambiguous. There 
are two considerable processes. One possibility is lactulose 
increased directly bifidobacteria and lactobacillus, conse-
quently it declined serum Cr and BUN level. Another is 
lactulose reduced uremic toxins, so it declined serum Cr 
and BUN level, consequently it increased bifidobacteria 
and lactobacillus. 
To consider the second possibility, we need to measure 
uremic toxins. We only evaluated blood levels of BUN and 
Cr and observed a significant reduction in Cr levels after 
lactulose administration, which had a significant increase 
in placebo group. Although not measuring the uremic tox-
ins in our study could be a great limitation to our findings; 
it could be concluded that lactulose could reduce uremic 
toxins; however, the exact mechanism and effect should 
be evaluated using p-cresol and other uremic toxins.
As mentioned, we only observed significant decrease in 
Cr levels in the intervention group and Cr increase in con-
trol group with no significant difference in BUN levels. 
However, in our previous study, we observed significant 
decrease in urea and Cr after treatment with lactulose 
(15). In another study, Miranda Alatriste and colleagues 
(35) only observed 11% reduction in BUN levels of CKD 
patients on probiotic supplementation. They concluded 
that lower dosage of supplementation, amount of protein 
consumption and small sample size can affect the result. 
It is possible that similar factors have role in the low non-
significant decrease of BUN in our study.
We also observed that Hb was maintained in the interven-
tion group while had significantly decreased in the con-
trol group. Cetin and colleagues (36) observed significant 
increase in RBC counts, Hct and Hb values in the group 
supplemented with probiotic compared with control. Such 
increase has also been reported in animal studies (37). 
However, in our previous study we observed no signifi-
cant difference between Hb values before and after treat-
ment (15). Considering these findings, it is possible that 
dietary probiotic and prebiotic supplementation such as 
lactulose may improve Hb levels in normal subjects and 
even in CKD patients. 
This study as the first study evaluating lactulose effects in 
CKD patients has some strengths and limitations; this is a 
randomized clinical trial with control group that allowed a 
better comparison of the results between groups and bet-
Table 3. Effect of 8-week ingestion of lactulose or placebo (30 mL, 
three times a day) on the fecal bacterial counts (mean ± SD; log 
CFU/g) in CKD patients
Intervention Control P value
Bifidobacterial counts 
(log CFU/g)
Before 3.61 ± 0.54 3.81 ± 0.70 0.37
At the end 4.90 ± 0.96 4.03 ± 0.90 0.01a
Lactobacilli counts (log 
CFU/g)
Before 2.79 ± 1.00 3.14 ± 1.28 0.39
At the end 3.87 ± 1.13 3.04 ± 1.14 0.04a
a P is two sided significant.
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ter evaluation of the lactulose efficacy. As a limitation we 
did not measure uremic toxins and could not evaluate the 
exact effects of lactulose on reducing these toxins by in-
fluencing the GIT. However, the reduction in the Cr levels 
and not increase in its values could be the effect of this 
prebiotic in this regard.
Conclusion
The results of current study showed that lactulose ad-
ministration will increase bifidobacteria and lactobacillus 
counts in patients with CKD. Considering our previous 
findings regarding the role of lactulose in reducing the 
uremic toxins, it is possible that increase bifidobacteria 
and lactobacillus counts can cause reduction of uremic 
toxins and also the BUN and Cr which would improve the 
function of the kidney in CKD patients. 
Limitations of the study 
The limitation of this study was small proportion of  pa-
tients. Thus we suggest more investigations on this aspect 
of kidney diseases patients.
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